Search research articles
Contact Us
Filters
Showing results (651-660 of 680) with videos related to
Page
of 68
Sort By:
Science Translational Medicine
|
April 2, 2025
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses
Thembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, et al.
Lancet (London, England)
|
December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials
Kayvon Modjarrad, Leyi Lin, Sarah L George, et al.
AIDS Research and Human Retroviruses
|
October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120
Nicos Karasavvas, Erik Billings, Mangala Rao, et al.
The Lancet. Respiratory Medicine
|
September 16, 2023
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
Gustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Plos Pathogens
|
July 20, 2016
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
Cecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 24, 2024
Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa
Betty Mwesigwa, Fredrick Sawe, Janet Oyieko, et al.
Plos Pathogens
|
September 26, 2017
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
Cecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
The Lancet. Infectious Diseases
|
July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
Kayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
The Journal of Infectious Diseases
|
April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Aging
|
August 14, 2020
Global variability of the human IgG glycome
Jerko Štambuk, Natali Nakić, Frano Vučković, et al.
Page
of 68
Search research articles
Search
Showing results (651-660 of 680) with videos related to
Sort By:
Page
of 68
Science Translational Medicine
|
April 2, 2025
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses
Thembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, et al.
Lancet (London, England)
|
December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials
Kayvon Modjarrad, Leyi Lin, Sarah L George, et al.
AIDS Research and Human Retroviruses
|
October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120
Nicos Karasavvas, Erik Billings, Mangala Rao, et al.
The Lancet. Respiratory Medicine
|
September 16, 2023
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
Gustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Plos Pathogens
|
July 20, 2016
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
Cecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 24, 2024
Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa
Betty Mwesigwa, Fredrick Sawe, Janet Oyieko, et al.
Plos Pathogens
|
September 26, 2017
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
Cecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
The Lancet. Infectious Diseases
|
July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
Kayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
The Journal of Infectious Diseases
|
April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Aging
|
August 14, 2020
Global variability of the human IgG glycome
Jerko Štambuk, Natali Nakić, Frano Vučković, et al.
Page
of 68